EDCTP's strategy for funding research on HIV

Fact sheet • May 2020

According to World Health Organization (WHO) statistics, in 2018 an estimated 1.7 million people were newly infected with HIV and there were 0.8 million HIV-related deaths. Most of these deaths are in low and middle-income countries, particularly in sub-Saharan Africa, where the burden of infectious diseases is highest and where vulnerable populations, such as adolescents, children, women and co-infected individuals, remain difficult to reach.

The UNAIDS Report 2019 states that 'in 2018, more than half of all new HIV infections were among key populations. Globally in 2018, 6000 adolescent girls and young women became infected with HIV every week. Current demographic trends in Africa foresee increasing numbers of young people at risk of HIV exposure. Moreover, in sub-Saharan Africa, four in five new HIV infections among adolescents aged 10–19 years are among girls.' In order to reduce the burden of new HIV infections, the high at-risk groups and communities need to be involved in research and clinical studies.

EDCTP portfolio 2014-2019: HIV & HIV-associated infections

EDCTP's strategic research agenda addresses treatment, prevention, and product-focused implementation research with prioritisation of the following needs:

- Optimised treatment regimens and drug formulations for key groups such as children, pregnant women and adults with co-infections and co-morbidities;
- Increased access to proven interventions; and
- Novel HIV prevention strategies such as pre-exposure prophylaxis and vaccines.

By end of 2019, EDCTP invested in 84 grants (total investment €526.04 million) of which 16 HIV & HIV-associated infections grants (total investment of €96.74 million).

HIV & HIV-associated infections

2014-2019

Collaborative clinical trials and clinical studies

16 grants

€96.74 M

Drugs
*10 grants*
€56.30 M

Vaccines
4 grants
€35.59 M

Diagnostics
2 grants
€4.85 M

EDCTP portfolio: HIV & HIV-associated infections

Drugs	Vaccines	Diagnostics

Drugs

CAPRISA 018
South Africa
● (Adults)

BREATHER Plus
Kenya, South Africa, Uganda, Zimbabwe
● (Adults) ● (Adolescents)

CHAPAS-4
Uganda, Zambia, Zimbabwe
● (Adolescents) ● (Children)

PREGART
Ethiopia, Uganda
● (Pregnant women)

AMBITION-cm
Botswana, Malawi, South Africa, Uganda, Zimbabwe
● (Adults)

VITALITY
Zambia, Zimbabwe
● (Children) ● (Adolescents)

CHAPS
South Africa, Uganda
● (Adults) ● (Adolescents)

META TRIAL
Tanzania
● (Adults)

PROMISE-EPI
Burkina Faso, Zimbabwe
● (Pregnant women)

5FC HIV-Crypto
Ethiopia, Uganda
● (Pregnant women)

Vaccines

GREAT
Kenya, Uganda, Zambia
● (Adults)

PrEPVacc
Mozambique, Tanzania, Uganda
● (Adults)

Neo bnAb
Mozambique, Tanzania
● (Pregnant women)

CAP012 SAMBA Trial
South Africa, Zambia
● (Adults)

Diagnostics

LIFE Study
Mozambique, Tanzania
● (Adults) ● (Pregnant women)

DREAMM
Tanzania, Malawi, Cameroon
● (Observational study) ● (Adults)

Caption

Project name
Site(s) in sub-Saharan Africa

Study phase	Population
Phase I	● Adults (18yr and above)
Phase II	● Adolescents (10yr-17yr)
Phase III	● Children (2yr-9yr)
Phase IV	● Infants (above 1mo-1yr)
Observational study	● Pregnant women and/or newborns (birth to 1mo)

Country participation in EDCTP-funded research on HIV and HIV-associated infections

- **Netherlands** — 5 grants
- **France** — 5 grants
- **United Kingdom** — 11 grants
- **Luxembourg** — 1 grant
- **Switzerland** — 2 grants
- **Norway** — 2 grants
- **Germany** — 3 grants
- **Sweden** — 3 grants
- **United States** — 3 grants
- **Spain** — 1 grant
- **Portugal** — 1 grant
- **Italy** — 2 grants
- **Ethiopia** — 1 grant
- **Kenya** — 2 grants
- **Tanzania** — 6 grants
- **Malawi** — 2 grants
- **Mozambique** — 3 grants
- **Uganda** — 6 grants
- **Burkina Faso** — 1 grant
- **Cameroon** — 1 grant
- **Zimbabwe** — 4 grants
- **South Africa** — 8 grants
- **Botswana** — 1 grant
- **Zambia** — 4 grants